Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 9/20 | 0.46 |
| ▸ | F2 | P00734 | 5/20 | 0.46 |
| ▸ | PLAU | P00749 | 5/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516455 | 0.90 | ELANE (0.54) | WDR5ELANEF2PLAUCTRB1 | |
| SCHEMBL27819361 | 0.86 | WDR5 (0.48) | WDR5ELANEF2PLAUCTRB1 | |
| SCHEMBL15081314 | 0.83 | ELANE (0.46) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL4991927 | 0.81 | ELANE (0.47) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL6597793 | 0.78 | CDK2 (0.53) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL18108643 | 0.76 | THRB (0.55) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3519191 | 0.75 | ELANE (0.56) | WDR5ELANEF2PLAUCTRB1 | |
| SCHEMBL2144637 | 0.75 | ELANE (0.47) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL30123629 | 0.75 | ELANE (0.47) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL4134609 | 0.74 | RAB9A (0.39) | KMT2ASMN1; SMN2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295413-A1 | Indazole compounds useful as protein kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295412-A1 | Indazole compounds useful as protein kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7041687-B2 | Indazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1467972-A1 | INDAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040009968-A1 | Indazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-01-15 | — | — | US | disclosed |
| WO-2003064397-A1 | INDAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009968-A1 | Indazole compounds useful as protein kinase inhibitors | PRKD3, PDPK1, PDK1 | WDR5 2018/4885ELANE 4722/4885F2 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.